Shares closed at $82.33 as the S&P 500 rose 0.84% to 7,398.93 and the Dow Jones Industrial Average edged up 0.02% to 49,609.16.
The stock finished 23.97% below its 52-week high of $108.29 reached on 26 August, while trading volume of 2.1 million was below its 50-day average.
Against peers, Johnson & Johnson fell 0.53%, Medtronic dropped 2.32% and Stryker declined 2.98%, leaving Zimmer Biomet weaker than the broader market but ahead of some rivals.
With record sales but a falling stock, is Zimmer Biomet a bargain or a value trap for investors?
Can Zimmer Biomet's new products overcome its internal turmoil and win the robotics race against rivals?
Will blockbuster weight-loss drugs ultimately help or harm the orthopedic device industry's long-term growth?